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Purpose: Vascular disorders and viral infections are considered the main causes of 
sudden hearing loss (SHL), although its pathogenesis remain unclear. Treatments 
include carbogen inhalation and lipo-prostaglandin E1 (lipo-PGE1), both of which 
have circulation-enhancing effects. We investigated the effectiveness of carbogen 
inhalation and lipo-PGE1 in SHL. Materials and Methods: This retrospective re-
view included 202 patients with idiopathic SHL who visited our clinic within 14 
days of symptom onset between January 2006 and June 2010. All patients re-
ceived oral prednisolone for 10 days. Of the 202 patients, 44 received no addition-
al treatment, 106 received additional carbogen inhalation, and 52 received addi-
tional lipo-PGE1. Hearing improvement was measured using Siegel’s criteria. 
Results: Overall recovery rates were 67.9% in the carbogen group, 53.8% in the 
lipo-PGE1 group, and 52.3% in the steroid-only control group (p=0.097). Limited 
to type 1 and type 2 categories of Sigels’s criteria, the carbogen group had a signif-
icantly higher recovery rate (53.8%) than the lipo-PGE1 group (26.9%) and the 
steroid-only control group (38.6%) (p=0.005). Conclusion: Carbogen inhalation 
added to steroid was a more effective treatment than lipo-PGE1 added to steroid or 
steroid alone in patients with SHL.
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INTRODUCTION
Sudden hearing loss (SHL)  is considered a syndrome and not a diagnosis and de-
fined as a hearing loss of at least 30 dB in three sequential frequencies occurring 
over 3 days or less.1 SHL was first reported by De Kleyn2 in 1944, there have been 
many studies regarding the disease, but the pathogenesis remains unclear. SHL in-
volves a variety of causative factors, and therefore should be considered a syn-
drome rather than a single disease.3 The most common causes include viral infec-
tion and vascular disorders; other causes include rupture of the inner ear 
membrane, immune disorders, and acoustic tumors.4
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physical examination, pure tone audiometry, speech audi-
ometry, and impedence audiometry. Auditory Brainstem 
Response latency and temporal magnetic resonance imag-
ing were selectively performed to rule out retrocochlear pa-
thology. To minimize the bias, we excluded patients who 
presented more than 14 days of symptom onset and patients 
with other causes of hearing loss such as Meniere’s disease, 
vestibular schwannoma, and ischemic brain lesion includ-
ing AICA infarct.
All patients received identical initial treatment consisting 
of 1 mg/kg of prednisolone (Solondo®, 5 mg tablets, Yuhan 
Corp., Seoul, Korea) administered orally for 5 days and 
then tapered for 5 days (a half-dose on days 6 and 7, 20 mg 
on days 8 and 9, and 10 mg on day 10). Patients were di-
vided into 3 groups: the steroid-only control group consist-
ed of 44 patients who presented between January 2006 and 
May 2007 and received no additional treatment, the carbo-
gen group consisted of 106 patients who presented between 
June 2007 and June 2009 and received additional carbogen 
inhalation treatment, and the lipo-PGE1 group consisted of 
52 patients who presented between July 2009 and June 
2010 and received additional lipo-PGE1 treatment. 
Carbogen inhalation treatment involved inhaling mixed 
gas (5% CO2, 95% O2) once a day for 1 hour for 5 days. Li-
po-PGE1 treatment involved daily intravenous injection of 5 
μg lipo-PGE1 mixed with 500 mL normal saline for 5 days.
Therapeutic effect analysis
The follow-up hearing testing schedule is given in Fig. 1. 
The Therapeutic effects were evaluated at least 2 months af-
ter end of treatment which known for hearing stabilazation,13 
using the pure tone average (average of the 0.5, 1.0, 2.0, and 
3.0 kHz hearing thresholds). We used Siegel’s criteria for 
hearing improvement analysis (Table 1). ‘Overall recovery’ 
was defined as showing any recovery after the conclusion of 
treatment (Siegel’s criteria I, II, and III). ‘Favorable recov-
The most widely accepted treatment for SHL is systemic 
corticosteroids,5 due to their ability to reduce inflammation, 
inhibit immune mechanisms, and regulate electrolyte bal-
ance. However, studies have shown that corticosteroid treat-
ment is not significantly more effective than placebo, and 
includes serious side effects.6,7 Thus there have been contin-
uous efforts to identify additional treatments.8 In the case of 
SHL caused by viral infection, studies on antiviral therapy 
have shown controversial therapeutic results.9 
Vasodilators such as carbogen inhalation and lipoprosta-
glandin E1 (lipo-PGE1) have been used to treat SHL based 
on the theory that vasodilation of the inner ear may aid re-
covery if caused by a vascular disorder. Lipo-PGE1 is a 
prostanoid that acts as a vasodilator and improves vascular 
circulation. Carbogen inhalation increases arterial oxygen 
saturation and maximizes oxygen supply to the inner ear. 
Studies on the effects of carbogen and lipo-PGE1 in SHL 
have had controversical results. Shea and Kitabchi10 report-
ed that carbogen inhalation had a therapeutic effect, while 
Cinamon, et al.6 found no therapeutic effect. Similarly, 
Zhuo, et al.11 reported that lipo-PGE1 had a therapeutic ef-
fect, while Ahn, et al.12 found no therapeutic effect. Despite 
controversial benefits, the theories remain that improving 
circulation may yield therapeutic results in cases where a 
vascular disorder underlies the SHL. 
In this study, we compared 2 vasodilator treatments for 
SHL, carbogen inhalation and lipo-PGE1, to investigate 
their therapeutic effects. 
MATERIALS AND METHODS
　　　
Patients
This retrospective review was performed in 236 patients 
with SHL who visited our clinic between January 2006 and 
June 2010. All patients underwent a thorough history and 
Fig. 1. Diagram for treatment and follow-up schedule. After a 10 day-course of corticosteroids and additional treatments, pure tone audiograms were mea-
sured. The final hearing test was performed at least 2 months after end of treatment. OPD, outpatient department.
Initial hearing Hearing at discharge
10 days
Admission & treatment Wait and hearing test in OPD base
>60 days
Final hearing
: Audiologic test
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en (45.5%). Their mean age was 49.6±16.9 years (range, 13 
to 89). The average time between symptom onset and pre-
sentation to clinic was 3.5±3.1 days. There were no signifi-
cant differences in age, gender, disease duration, follow-up 
period, or initial hearing threshold of the affected ear be-
tween groups (Table 2). 
Hearing change
Overall average hearing thresholds before and after treat-
ment were 73.2±27.6 dB and 47.1±31.7 dB, respectively. 
Overall recovery was achieved by 123 patients (60.9%), 88 
(43.6%) of whom achieved favorable recovery, which cor-
responds to Siegel’s criteria I and II.
Comparing the recovery rate by the criteria of overall re-
covery, 72 of 106 (67.9%) in the carbogen group, 28 of 52 
(53.8%) in the lipo-PGE1 group, and 23 of 44 (52.3%) in the 
control group attained hearing recovery. The higher rate of 
overall recovery in the carbogen group was not statistically 
significant (p=0.097). However, when comparing favorable 
recovery, the carbogen group (53.8%) experienced a signifi-
cantly higher recovery rate than did the lipo-PGE1 group 
(26.9%) or the control group (38.6%) (p=0.005) (Fig. 2).
In regards to RHG, the carbogen group had higher RHG 
(29.58 dB) than did the lipo-PGE1 group (20.15 dB) or the 
control group (21.48 dB), but the difference was not statisti-
cally significant (p=0.033) (Table 3). 
Word recognition score improved in correlation with av-
ery’ was defined as final hearing corresponding to Siegel’s 
criteria I and II. We compared the hearing recovery rate and 
the degree of hearing recovery between groups. We com-
pared the average relative hearing gain (RHG; hearing dif-
ference between pre- and post- pure tone threshold) between 
the 3 groups. 
Given that serviceable hearing is important in patients with 
SHL, we also segmentally repeated same analysis limited to 
patients with more than moderate-severe initial hearing loss 
(initial hearing level over 56 dB). RHG was compared be-
tween 3 groups in patients who had more than moderate-se-
vere initial hearing loss and RHG was also analyzed accord-
ing to frequencies in same patients.
Statistical analysis
Significant differences between groups were determined 
using the chi-square test, Fisher’s exact test, and one-way 
ANOVA, with p<0.05 defined as the cut-off for statistical 
significance. All statistical analysis was performed using 
SPSS v16.0.
 
RESULTS
 
Patient characteristics 
202 out of 236 patients with SHL were included in this 
study and were consisted of 110 men (54.5%) and 92 wom-
Table 1. Siegel’s Criteria of Hearing Recovery
Type Hearing recovery
I. Complete recovery Final hearing better than 25 dB
II. Partial recovery More than 15 dB gain, final hearing 25-45 dB
III. Slight improvement More than 15 dB gain, final hearing poorer than 45 dB
IV. No improvement Less than 15 dB gain, final hearing poorer than 75 dB
Table 2. General and Hearing Characteristics of Patients
Clinical characteristics Control (n=44) Lipo-PGE1 (n=52) Carbogen (n=106) p value
Age (yrs) 48.61±17.55 44.88±17.45 50.92±15.37 0.095*
Gender (male : female) 25 : 19 28 : 24 57 : 49 0.947†
Ear (right : left) 21 : 23 18 : 34 55 : 51 0.123†
Symptom duration (days) 3.57±3.51 3.23±2.85 3.60±2.99 0.762*
Mean follow-up (days) 54.35±29.10 50.74±16.44 51.67±40.31 0.925*
Rates of systemic disease (%) 5/44 (11.4) 4/52 (7.7) 14/106 (13.2)  0.698‡
Initail hearing threshold (dB) 74.64±29.36 81.00±28.75 70.74±26.38 0.091*
Initial pattern of hearing 
  (LFHL : HFHL : flat : others)  
9 : 10 : 11 : 13 10 : 8 : 20 : 14 15 : 20 : 31 : 40  0.587‡
LFHL, low frequency hearing loss; HFHL, high frequency hearing loss; lipo-PGE1, lipo-prostaglandin E1.
*One way ANOVA test was used.
†Chi-square test was used. 
‡Fisher’s exact test was used.
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in overall and favorable recovery (p=0.712 and p=0.756, re-
spectively) (data not shown).
Complications
There were no major complications during treatment. Al-
though several patients experienced severe hyperglycemia, the 
patients’ blood glucose level were normalized after the end of 
treatment. The incidence of hyperglycemia was not significant-
ly different between groups (data not shown) and it was likely 
due to the side effect of the systemic corticosteroids. 
DISCUSSION
Although the underlying mechanism of SHL is unknown, 
erage pure tone threshold and there was no statistical differ-
ence (p=0.291) (data not shown).
We examined the treatment efficacy in patients with initial 
hearing level over 56 dB (n=132). In this subset, the carbo-
gen group (n=73) had significantly higher rates of overall 
and favorable recovery (p=0.008 and p=0.001, respectively) 
(Fig. 3). In addition, the carbogen group had significantly 
higher RHG than the other groups (p=0.002) (Table 3). 
However, when RHG was categorized into frequencies, 
there was no significant difference between groups except 
2.0 kHz (Fig. 4).
If limited to patients with profound hearing loss (n=55), 
the carbogen group (n=30) tended to have better treatment 
effect compared to control group (n=15) or lipo-PGE1 group 
(n=10), but there was no statistical difference between groups 
Table 3. Degree of Hearing Recovery (dB) according to Initial Hearing Level between Group
Initial hearing level Control (n) PGE1 (n) Carbogen (n) p value
<56 dB 16.73±14.31 (11) 16.75±12.58 (30) 14.45±16.88 (33) 0.881*
≥56 dB 23.06±25.22 (33) 20.77±21.85 (22) 36.42±26.20 (73) 0.002*
Overall 21.48±22.99 20.15±20.55 29.58±25.73 0.033*
PGE, prostaglandin E1.
*One way ANOVA test was used. 
Fig. 2. Final hearing results after treatment according to Siegel’s criteria. The ‘overall’ recovery rate (Sigel’s type I, II, and III) of the carbogen group (72 of 106, 
67.9%) was higher than that of the lipo-PGE1 group (28 of 52, 53.8%) and the control group (23 of 44, 52.3%), although the difference was not statistically sig-
nificant (p=0.097). The ‘favorable’ recovery (Sigel’s type I and II) rate of the carbogen group (57 of 106, 53.8%) was significantly higher than that of the lipo-
PGE1 group (14 of 52, 26.9%) and the control group (17 of 44, 38.6%) (p=0.005). The chi-square test was used. lipo-PGE1, lipo-prostaglandin E1.
Fig. 3. Final hearing results after treatment according to Siegel’s criteria in patients with ≥56 dB initial hearing. The ‘overall’ recovery (Sigel’s type I, II, and III) 
rate of the carbogen group (52 of 73, 71.2%) was significantly higher than that of the lipo-PGE1 group (11 of 22, 50.0%) and the control group (14 of 33, 42.5%) 
(p=0.011). In addition, the ‘favorable’ recovery (Sigel’s type I and II) rate of the carbogen group (37 of 73, 50.7%) was significantly higher than that of the lipo-
PGE1 group (4 of 22, 18.1%) and the control group (8 of 33, 24.3%) (p=0.004). The chi-square test and Fischer’s exact test were used. lipo-PGE1, lipo-prosta-
glandin E1.
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oxygen saturation as measured by perilymphic oxygen sat-
uration. Furthermore, Kallinen, et al.20 reported that carbo-
gen inhalation is an effective treatment for high frequency 
hearing loss, although there was no significant difference in 
RHG in frequencies between patients receiving carbogen 
and those receiving lipo-PGE1 in this study. 
In this study, carbogen inhalation had advantages over li-
po-PGE1 and steroids alone particularly in patients with an 
initial hearing level over 56 dB. This benefit may be due to 
the vasodilatory effects of CO2 along with the increased ox-
ygen partial pressure in the inner ear. Paradoxically, al-
though PGE1 and lipo-PGE1 are reported to improve co-
chlear blood flow, they simultaneously decrease systemic 
blood flow.21 These may explain the reasons for the failure 
of increase in inner ear oxygen partial pressure.
In conclusion, SHL has a variety of causes and is current-
ly treated with combination modalities. Our findings suggest 
that efficacy of carbogen inhalation treatment is positive and 
it can be a reasonable addition to oral corticosteroids to tar-
get the vascular component. 
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